50
Participants
Start Date
August 30, 2022
Primary Completion Date
August 30, 2024
Study Completion Date
January 15, 2025
Bictegravir/emtricitabine/tenofovir alafenamide
Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
Collaborators (1)
Gilead Sciences
INDUSTRY
Valley AIDS Council
OTHER